Select Topics in Cardiovascular Medicine

Slides:



Advertisements
Similar presentations
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
Advertisements

Polypill x Aspirin Project Groups 3 and 4
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
The Anglo Scandinavian Cardiac Outcomes Trial
The Latest Lipid Guidelines:
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
PCSK9 Inhibitors Post-CVOTs
Statin Selection in the Elderly
Current Dyslipidemia Management Guidelines Residual Risk.
An Endocrinology Clinic in Dyslipidemia
Omega-3 Prescriptions vs Supplements in Practice
Systolic Blood Pressure Intervention Trial (SPRINT)
A New Era for NOACs:.
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
CV Risk Management in T2DM: What Did We Learn From EASD 2016?
Managing Complex Hypertension: What Every Physician Should Know
Advances in Dyslipidemia: What Have We Learned From ACC 2017
Managing Hard-To-Treat Hypertension: What Every Physician Should Know
Antithrombotics and PAD: A New Paradigm in Practice
New Perspectives in CAD and PAD: Weighing the Latest Evidence
Beyond Statin Therapy.
The Chemical Differences Between EPA and DHA.
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
T2DM and CV Outcomes Trials: A Deep Dive!
Diabetes Increases Risk of CVD
An Update on PCSK9 Inhibitors
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.
Evaluating LDL-C Recommendations
What's New in Dyslipidemia?
Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.
CV Risk Doesn't End in the Cath Lab
Personalizing Statin Therapy in Patients With HIV
PCSK9 Inhibitors and Cardiovascular Outcomes
Tackling CV Risk in T2DM.
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Risk Stratification in CAD and PAD
Statins and HIV:.
CV Risk Management in T2DM: What Did We Learn from ADA 2016?
LEADER One Year On.
CV Risk Doesn't End in the Cath Lab
Clinicians' Corner in Dyslipidemia
Updates in Cardiovascular Medicine
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Factor Xa Inhibitors in PAD
T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight
CAD/PAD in Primary Care
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
Antithrombotic Therapy in PAD
Iron Deficiency in Heart Failure
LDL Cholesterol.
How to Optimize Cholesterol Management in High-Risk CV Patients
Reducing Risk for CV Outcomes
Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.
Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?
Factor Xa Inhibitors in Coronary Artery Disease
HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.
Lipid Updates From Spring 2019
New Lipid-Lowering Therapies
An Update on PCSK9 Inhibitors
2015 EASD In Review: CV Risk management in t2dm
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future
Reassessing Risk Stratification in CAD/PAD
Lipids, the Heart, and the Kidney
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
PCSK9 Inhibitors and Real-World Evidence
Translating Data From Trial to Practice
Presentation transcript:

Select Topics in Cardiovascular Medicine

Agenda

Cardiovascular Disease in Latin America

Prevalence Rates of CV Risk Factors: Results From Several Studies in Latin Americans

CV Mortality in Latin America

CV Risk Factor Reduction: Combination Therapy vs Placebo

Baseline Factors Associated With 4-Year Outcomes in Latin American Patients of the REACH Registry

Summary and Conclusions

An Integral Approach to Hypertension

ESH/ESC/JNC8 BP Treatment Recommendations

Results From the SPRINT Trial: SBP > 130? > 120?

Controversy Surrounding BP Measurement in SPRINT

Masked and NTH in the ARTS-DN ABPM Substudy With Finerenone

Treating Prehypertension to Reduce Incidence of CV Disease/Events

Summary and Conclusions

New Insights Into Dyslipidemia Therapy: Controlling Lipids to Reduce CV Risk

Changes in CV Mortality in Selected Regions, 1990-2013

Intervention Strategies Based on CV Risk Factors and Cholesterol Levels

Targets and Strategies for Cholesterol Reduction: Moving Beyond Statins

PCSK9 Inhibitors for Dyslipidemia: Results of the FOURIER Study

Summary and Conclusions

Heart Failure: How Can We Improve Timely Diagnosis and Effective Treatment?

Death Rates for Patients Hospitalized With HF: Europe and Latin America

Common Comorbidities Associated With HF

HF: Diagnostic Algorithm

Primary Endpoint Results: CANTOS

Effects of FCM on Hospitalizations and Mortality Rates: A Meta-Analysis

Summary and Conclusions

Future Strategies for the Prevention of CVD in Latin America

Introduction and Overview

COMPASS: Rivaroxaban With or Without Aspirin in Stable CVD

Cumulative Incidence of the Primary Outcome (CV Death, Stroke, or MI)

COMPASS Subgroup Analysis: PAD

COMPASS Results: Net Clinical Benefit

CANTOS Trial: Study Design

CANTOS Trial: Primary Endpoint Results

CANTOS Trial: Selected AEs

New Treatments and Cost/Benefit Considerations in Latin America

Selected Risk Factors: Results From the INTERHEART Latin America Study

Summary and Conclusions

Select Topics in Cardiovascular Medicine

Summary and Conclusions (1 of 2)

Summary and Conclusions (2 of 2)

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)